Dr. Donoghue is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3101 Ellicott St Nw
Washington, DC 20008Phone+1 202-487-9658Fax+1 202-476-5685
Education & Training
- Children's National Hospital/George Washington UniversityFellowship, Pediatric Hematology/Oncology, 2006 - 2009
- MedStar Health/Georgetown University HospitalResidency, Pediatrics, 1995 - 1998
- Emory University School of MedicineClass of 1995
Certifications & Licensure
- DC State Medical License 1998 - 2024
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy.Elizabeth S Duke, Diana Bradford, Arup K Sinha, Pallavi S Mishra-Kalyani, Catherine C Lerro
Journal of Clinical Oncology. 2024-09-01 - Review of Racial and Ethnic Representation of Participants Enrolled in Pediatric Clinical Trials of Oncology Drugs Conducted Through FDA Written Requests.Lola A Fashoyin-Aje, Alemayehu Y Akalu, Jessica Boehmer, Richard Pazdur, Martha Donoghue
JAMA Oncology. 2024-03-01 - 8 citationsFDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.Michael I Barbato, Jeannette Nashed, Diana Bradford, Yi Ren, Sachia Khasar
Clinical Cancer Research. 2024-01-17
Press Mentions
- ODAC Meets to Assess FDA Reauthorization Act ChangesJune 5th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: